Scholarlink

Background <p>Allogeneic hematopoietic stem cell transplantation (HSCT) is a curative option for patients with hematologic malignancies, but the limited availability of HLA-matched sibling donors necessitates alternative graft sources. Haploidentical donors (HIDs) and double-unit umbilical cord blood (DUCB) are two widely used alternatives, yet direct comparisons of their clinical outcomes remain limited.</p> Methods <p>We conducted a retrospective single-center study of 97 patients with hematologic malignancies who underwent HSCT between August 2014 and May 2024. Patients received either HID transplantation (<i>n</i> = 57) or DUCB transplantation (<i>n</i> = 40). Hematopoietic recovery, graft-versus-host disease (GVHD), and long-term survival outcomes were assessed using cumulative incidence and Kaplan–Meier analyses, with multivariate Cox regression applied to identify prognostic factors.</p> Results <p>HID recipients achieved significantly faster neutrophil (median: 14.00 vs. 22.50 days) and platelet recovery (median: 15.00 vs. 44.50 days) than DUCB recipients (both <i>P</i> &lt; 0.001). The incidence of grade II–IV acute GVHD (16.80% vs. 47.70%, <i>P</i> &lt; 0.001) and chronic GVHD (10.30% vs. 28.60%, <i>P</i> = 0.033) was lower in the HID group, although severe grade III–IV aGVHD rates were comparable (13.00% vs. 23.90%, <i>P</i> = 0.160). Five-year overall survival (56.70% HID vs. 48.90% DUCB, <i>P</i> = 0.573), relapse-free survival (76.60% vs. 89.70%, <i>P</i> = 0.210), GVHD-free relapse-free survival (48.00% vs. 46.30%, <i>P</i> = 0.410), and non-relapse mortality (NRM) (35.40% vs. 47.00%, <i>P</i> = 0.188) did not differ significantly between groups.</p> Conclusion <p>Both HID and DUCB transplantation are viable alternatives in the absence of an HLA-matched sibling donor. However, HID transplantation offers faster hematopoietic recovery and a reduced GVHD burden, which may provide practical clinical advantages when donor availability permits.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Haploidentical donor versus double-unit cord blood transplantation in hematologic malignancies: comparative survival and graft-versus-host disease outcomes from a decade of real-world experience

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年5月22日

查看全文
  • Rui Liu,
  • Jie Zhao,
  • Xiaohui Deng,
  • Yan Jiang,
  • Siguo Hao,
  • Jiangbo Wan

摘要

Background

Allogeneic hematopoietic stem cell transplantation (HSCT) is a curative option for patients with hematologic malignancies, but the limited availability of HLA-matched sibling donors necessitates alternative graft sources. Haploidentical donors (HIDs) and double-unit umbilical cord blood (DUCB) are two widely used alternatives, yet direct comparisons of their clinical outcomes remain limited.

Methods

We conducted a retrospective single-center study of 97 patients with hematologic malignancies who underwent HSCT between August 2014 and May 2024. Patients received either HID transplantation (n = 57) or DUCB transplantation (n = 40). Hematopoietic recovery, graft-versus-host disease (GVHD), and long-term survival outcomes were assessed using cumulative incidence and Kaplan–Meier analyses, with multivariate Cox regression applied to identify prognostic factors.

Results

HID recipients achieved significantly faster neutrophil (median: 14.00 vs. 22.50 days) and platelet recovery (median: 15.00 vs. 44.50 days) than DUCB recipients (both P < 0.001). The incidence of grade II–IV acute GVHD (16.80% vs. 47.70%, P < 0.001) and chronic GVHD (10.30% vs. 28.60%, P = 0.033) was lower in the HID group, although severe grade III–IV aGVHD rates were comparable (13.00% vs. 23.90%, P = 0.160). Five-year overall survival (56.70% HID vs. 48.90% DUCB, P = 0.573), relapse-free survival (76.60% vs. 89.70%, P = 0.210), GVHD-free relapse-free survival (48.00% vs. 46.30%, P = 0.410), and non-relapse mortality (NRM) (35.40% vs. 47.00%, P = 0.188) did not differ significantly between groups.

Conclusion

Both HID and DUCB transplantation are viable alternatives in the absence of an HLA-matched sibling donor. However, HID transplantation offers faster hematopoietic recovery and a reduced GVHD burden, which may provide practical clinical advantages when donor availability permits.